Monthly Archives: September 2023

Enhancing Efficacy of Albumin-Bound Paclitaxel for Human Lung and Colorectal Cancers through Autophagy Receptor Sequestosome 1 (SQSTM1)/p62-Mediated Nanodrug Delivery and Cancer therapy

趙瑞益教授研究團隊發表研究成果於ACS Nano

連結網址:https://pubmed.ncbi.nlm.nih.gov/37737568/

Abstract

Selective autophagy is a defense mechanism by which foreign pathogens and abnormal substances are processed to maintain cellular homeostasis. Sequestosome 1 (SQSTM1)/p62, a vital selective autophagy receptor, recruits ubiquitinated cargo to form autophagosomes for lysosomal degradation. Nab-PTX is an albumin-bound paclitaxel nanoparticle used in clinical cancer therapy. However, the role of SQSTM1 in regulating the delivery and efficacy of nanodrugs remains unclear. Here we showed that SQSTM1 plays a crucial role in Nab-PTX drug delivery and efficacy in human lung and colorectal cancers. Nab-PTX induces SQSTM1 phosphorylation at Ser403, which facilitates its incorporation into the selective autophagy of nanoparticles, known as nanoparticulophagy. Nab-PTX increased LC3-II protein expression, which triggered autophagosome formation. SQSTM1 enhanced Nab-PTX recognition to form autophagosomes, which were delivered to lysosomes for albumin degradation, thereby releasing PTX to induce mitotic catastrophe and apoptosis. Knockout of SQSTM1 downregulated Nab-PTX-induced mitotic catastrophe, apoptosis, and tumor inhibition in vitro and in vivo and inhibited Nab-PTX-induced caspase 3 activation via a p53-independent pathway. Ectopic expression of SQSTM1 by transfection of an SQSTM1-GFP vector restored the drug efficacy of Nab-PTX. Importantly, SQSTM1 is highly expressed in advanced lung and colorectal tumors and is associated with poor overall survival in clinical patients. Targeting SQSTM1 may provide an important strategy to improve nanodrug efficacy in clinical cancer therapy. This study demonstrates the enhanced efficacy of Nab-PTX for human lung and colorectal cancers via SQSTM1-mediated nanodrug delivery.

Controlling Circularly Polarized Luminescence Using Helically Structured Chiral Silica as a Nanosized Fused Quartz Cell

李明家副教授研究團隊發表研究成果於JACS Au,並獲選該期刊封面故事。

連結網址:https://pubs.acs.org/doi/10.1021/jacsau.3c00390

Abstract

Circularly polarized luminescence (CPL) is typically achieved with a chiral luminophore. However, using a helical nanosized fused quartz cell consisting of chiral silica, we could control the wavelength and helical sense of the CPL of an achiral luminophore. Chiral silica with a helical nanostructure was prepared by calcining a mixture of polyhedral oligomeric silsesquioxane (POSS)-functionalized isotactic poly(methacrylate) (it-PMAPOSS) and a small amount of chiral dopant. The chiral silica encapsulated functional molecules, including luminophores, along the helical nanocavity, leading to induced circular dichroism (ICD) and induced circularly polarized luminescence (iCPL). Because chiral silica can act as a helical nanosized fused quartz cell, it can encapsulate not only the luminophore but also solvent molecules. By changing the solvent in the luminophore-containing nanosized fused quartz cell, the wavelength of the CPL was controlled. This method provides an effective strategy for designing novel CPL-active materials.

中原大學辦理「AI在生物科技之應用成果發表會」

中原大學辦理「AI在生物科技之應用成果發表會」,邀請踴躍報名參加,請查照並惠予公告周知。說明:

一、本活動將邀請學有專精的教授群分享AI在運動追蹤、心臟生理以及皮膚傷口癒合方面的應用。

二、相關資訊如下:

(一)主辦單位:奈米科技中心(水生生物毒理與藥理服務平台)。

(二)時間:112年10月20日(星期五)10時至15時。

(三)地點:本校生物科技館101室。

(四)對象:各大專校院師生。

(五)費用:免費。

(六)報名表單網址:https://reurl.cc/1GjL98。

en_US